The burden of disease is heavy, and there is a huge clinical demand

At present, China has become the country with the highest number of Alzheimer's disease (AD) cases worldwide, with nearly 10 million patients. It is predicted that the number of Alzheimer's disease patients will be between 27.65 million and 91.94 million by 2050. According to an article in the neurology sub journal of The Lancet, China spends as much as $167.7 billion annually on Alzheimer's disease, of which more than half are indirect costs, such as losses incurred by patients and their families due to nursing delays. It is expected to increase tenfold to $1.89 trillion by 2050. At present, the effective clinical treatment methods in China are very limited. The drugs mainly target cholinesterase inhibitors for symptom improvement, such as donepezil and NMDA receptor antagonist memantine, which mainly improve symptoms in the short term but have no impact on the course of the disease. There is a huge gap in clinical unmet treatment needs.

Early detection and intervention maximize patient benefits

Alzheimer's disease is a progressive neurodegenerative disease with a hidden onset. In clinical practice, comprehensive dementia is characterized by memory impairment, aphasia, aphasia, agnosia, impairment of visual and spatial skills, and executive dysfunction. The etiology is still unknown. Premature dementia refers to individuals who develop symptoms before the age of 65; Individuals who develop dementia after the age of 65 are referred to as senile dementia. At present, the public generally lacks awareness of early intervention and is prone to missing the "golden window" of treatment, such as the mild cognitive impairment stage (MCI) or even earlier preclinical stages.

Disease modification therapy brings dawn to early AD patients

Due to the complex disease mechanisms and long-term and complex clinical trials of Alzheimer's disease, the emergence of Disease Modifying Therapy (DMT) has "epoch-making significance". Its core lies in its intervention in the pathogenesis of the disease, rather than just relieving symptoms or managing them.

The main pathogenesis of AD is the excessive production of β- Amyloid Beta, A β）， The ability to clear is reduced, and then these abnormal protein deposits form "plaques", leading to nerve cell death and affecting nerve signal transduction. One of the principles of DMT is to target the elimination of these "plaques" and solve the problem from the source. In 2023, lencamab will become the first fully approved anti-A drug by the US FDA in 20 years β Disease modifying drugs indicate that the treatment of Alzheimer's disease has moved from the era of symptomatic treatment to the era of causal treatment, and a new door of hope has opened. The approval of lencamab in Lecheng will enable some Chinese patients to use advanced AD drugs from around the world earlier.